TB-500

Mechanism

TB-500 is a synthetic fragment of Thymosin Beta-4, a ubiquitous 43-amino-acid protein involved in actin cytoskeleton regulation. Its core action is G-actin sequestration — binding monomeric actin to facilitate rapid cell migration toward injury sites. This makes it distinctly systemic in character: unlike BPC-157, which works best when injected close to the lesion, TB-500 circulates and recruits repair cells across multiple tissue compartments simultaneously. Remote injection still delivers full effect.

The peptide drives angiogenesis through upregulation of VEGF and promotes stem cell recruitment and differentiation at wound sites. It also modulates the inflammatory response by downregulating pro-inflammatory cytokines while preserving the initial acute phase needed for tissue remodelling. The net result is accelerated repair of muscle, tendon, and ligament tissue with reduced scar formation.

Mechanistically, TB-500 and BPC-157 operate through complementary but non-overlapping pathways — TB-500 through actin dynamics and cell migration, BPC-157 through nitric oxide and VEGFR2. Combining them produces an additive effect across the full wound-healing cascade.

Typical protocol

• Starter (loading phase): 5 mg/week split across three injections (Mon/Wed/Fri at ~1.67 mg each) for 4 weeks. This saturates the repair cascade during the acute injury window.
• Maintenance phase: 2–2.5 mg/week (single or split doses) for another 4 weeks after loading.
• Cycle length: 8 weeks total (4 loading + 4 maintenance), then 4 weeks off. Re-run if injury is ongoing.
• Reconstitution: 5 mg vial + 2 mL BAC water → 2.5 mg/mL. 40 IU on a U-100 insulin syringe = 1 mg.

Who it's for

Recovery goal. Muscle belly tears, tendon and ligament injuries, and connective tissue repair are the primary indications. Because the action is systemic, TB-500 suits diffuse or bilateral injuries where local BPC injection logistics are impractical. Athletes managing accumulated connective tissue wear also use it in maintenance blocks. Pair with BPC-157 for comprehensive soft-tissue work covering both angiogenesis and cell-migration axes.

Stacks well with

• bpc 157 5mg — complementary mechanisms covering the full soft-tissue repair cascade; BPC handles angiogenesis, TB-500 handles actin remodelling and cell recruitment.
• ghk cu 50mg — adds the collagen and elastin layer to the repair stack, addressing extracellular matrix quality alongside cellular migration.
• beauty stack bpc tb500 ghk — pre-bundled combination of BPC-157, TB-500, and GHK-Cu for full connective-tissue and recovery coverage.

Watch-outs

• Slow onset is expected — the ~2-day half-life means meaningful tissue effects accumulate around week 2, not day 3. Don't front-load expectations or abandon the protocol early.
• Systemic anti-inflammatory action can blunt acute inflammatory adaptation. Overlapping a full TB-500 loading phase with a high-volume training block risks attenuating the hypertrophic signalling that depends on controlled inflammation. Use during deload or rehab phases.
• Does not provide fast pain relief on day 1. It's a repair driver, not an analgesic — manage acute pain separately.